Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 3/2002

01-04-2002 | Review

Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors

Authors: Matthew P Vincenti, Constance E Brinckerhoff

Published in: Arthritis Research & Therapy | Issue 3/2002

Login to get access

Abstract

Matrix metalloproteinase (MMP)-1, MMP-8 and MMP-13 are interstitial collagenases that degrade type II collagen in cartilage; this is a committed step in the progression of rheumatoid arthritis and osteoarthritis. Of these enzymes, the expression of MMP-1 and MMP-13 is substantially increased in response to IL-1 and tumor necrosis factor-α, and elevated levels of these collagenases are observed in arthritic tissues. Therefore, cytokine-mediated MMP-1 and MMP-13 gene regulation is an important issue in arthritis research. In this review, we discuss current models of MMP-1 and MMP-13 transcriptional regulation, with a focus on signaling intermediates and transcription factors that may be future targets for the development of new arthritis drugs.
Literature
1.
Vincenti MP: The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol Biol. 2001, 151: 121-148.PubMed
2.
Nagase H, Woessner JF: Matrix metalloproteinases. J Biol Chem. 1999, 274: 21491-21494. 10.1074/jbc.274.31.21491.PubMedCrossRef
3.
Stetler-Stevenson WG, Yu AE: Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol. 2001, 11: 143-152. 10.1006/scbi.2000.0365.PubMedCrossRef
4.
Borden P, Heller RA: Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryotic Gene Expr. 1997, 7: 159-178.CrossRef
5.
Vincenti MP, White LA, Schroen DJ, Benbow U, Brinckerhoff CE: Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryotic Gene Expr. 1996, 6: 391-411.CrossRef
6.
Borden P, Solymar D, Sucharczuk A, Lindman B, Cannon P, Heller RA: Cytokine control of interstitial collagenase and col-lagenase-3 gene expression in human chondrocytes. J Biol Chem. 1996, 271: 23577-23581. 10.1074/jbc.271.38.23577.PubMedCrossRef
7.
Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE: Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 2000, 43: 801-811. 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4.PubMedCrossRef
8.
Vincenti MP, Coon CI, Mengshol JA, Yocum S, Mitchell P, Brinckerhoff CE: Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1). Biochem J. 1998, 331: 341-346.PubMedPubMedCentralCrossRef
9.
Brinckerhoff CE, Rutter JL, Benbow U: Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000, 6: 4823-4830.PubMed
10.
Goldring MB: The role of the chondrocyte in osteoarthritis. Arthritis Rheum. 2000, 43: 1916-1926. 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I.PubMedCrossRef
11.
Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS: c-Jun N-terminal kinase is required for met-alloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001, 108: 73-81. 10.1172/JCI200112466.PubMedPubMedCentralCrossRef
12.
Vincenti MP, Brinckerhoff CE: The potential of signal transduction inhibitors for the treatment of arthritis: Is it all just JNK?. J Clin Invest. 2001, 108: 181-183. 10.1172/JCI200113508.PubMedPubMedCentralCrossRef
13.
Tetlow LC, Adlam DJ, Woolley DE: Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum. 2001, 44: 585-594. 10.1002/1529-0131(200103)44:3<585::AID-ANR107>3.3.CO;2-3.PubMedCrossRef
14.
Shlopov BV, Lie WR, Mainardi CL, Cole AA, Chubinskaya S, Hasty KA: Osteoarthritic lesions: involvement of three different collagenases. Arthritis Rheum. 1997, 40: 2065-2074.PubMedCrossRef
15.
Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE: Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest. 1996, 97: 761-768.PubMedPubMedCentralCrossRef
16.
Firestein GS, Paine MM, Littman BH: Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitative analysis and effect of intraarticular corticos-teroids. Arthritis Rheum. 1991, 34: 1094-1105.PubMedCrossRef
17.
Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE: The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1993, 36: 372-379.PubMedCrossRef
18.
Westhoff CS, Freudiger D, Petrow P, Seyfert C, Zacher J, Kriegsmann J, Pap T, Gay S, Stiehl P, Gromnica-Ihle E, Wernicke D: Characterization of collagenase 3 (matrix metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis. Arthritis Rheum. 1999, 42: 1517-1527. 10.1002/1529-0131(199907)42:7<1517::AID-ANR27>3.0.CO;2-G.PubMedCrossRef
19.
Garrington TP, Johnson GL: Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol. 1999, 11: 211-218. 10.1016/S0955-0674(99)80028-3.PubMedCrossRef
20.
21.
Kolch W: Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000, 351: 289-305. 10.1042/0264-6021:3510289.PubMedPubMedCentralCrossRef
22.
Karin M: The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995, 270: 16483-16486.PubMedCrossRef
23.
Leppa S, Saffrich R, Ansorge W, Bohmann D: Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation. Embo J. 1998, 17: 4404-4413. 10.1093/emboj/17.15.4404.PubMedPubMedCentralCrossRef
24.
Janknecht R, Ernst WH, Nordheim A: SAP1a is a nuclear target of signaling cascades involving ERKs. Oncogene. 1995, 10: 1209-1216.PubMed
25.
O'Hagan RC, Tozer RG, Symons M, McCormick F, Hassell JA: The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades. Oncogene. 1996, 13: 1323-1333.PubMed
26.
Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K: The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature. 1999, 398: 252-256. 10.1038/18465.PubMedCrossRef
27.
Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000, 18: 621-663. 10.1146/annurev.immunol.18.1.621.PubMedCrossRef
28.
Bondeson J, Brennan F, Foxwell B, Feldmann M: Effective adenoviral transfer of IkappaBalpha into human fibroblasts and chondrosarcoma cells reveals that the induction of matrix metalloproteinases and proinflammatory cytokines is nuclear factor-kappaB dependent. J Rheumatol. 2000, 27: 2078-2089.PubMed
29.
Barchowsky A, Frleta D, Vincenti MP: Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine. 2000, 12: 1469-1479. 10.1006/cyto.2000.0743.PubMedCrossRef
30.
Vincenti MP, Coon CI, Brinckerhoff CE: Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis Rheum. 1998, 41: 1987-1994. 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#.PubMedCrossRef
31.
Xiao G, Harhaj EW, Sun SC: NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell. 2001, 7: 401-409.PubMedCrossRef
32.
Heissmeyer V, Krappmann D, Hatada EN, Scheidereit C: Shared pathways of IkappaB kinase-induced SCF(betaTrCP)-mediated ubiquitination and degradation for the NF-kappaB precursor p105 and IkappaBalpha. Mol Cell Biol. 2001, 21: 1024-1035. 10.1128/MCB.21.4.1024-1035.2001.PubMedPubMedCentralCrossRef
33.
Heusch M, Lin L, Geleziunas R, Greene WC: The generation of nfkb2 p52: mechanism and efficiency. Oncogene. 1999, 18: 6201-6208. 10.1038/sj/onc/1203022.PubMedCrossRef
34.
Heissmeyer V, Krappmann D, Wulczyn FG, Scheidereit C: NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes. Embo J. 1999, 18: 4766-4778. 10.1093/emboj/18.17.4766.PubMedPubMedCentralCrossRef
35.
Ziegler-Heitbrock HW, Wedel A, Schraut W, Strobel M, Wendel-gass P, Sternsdorf T, Bauerle PA, Haas JG, Riethmuller G: Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. J Biol Chem. 1994, 269: 17001-17004.PubMedCrossRef
36.
Franzoso G, Bours V, Azarenko V, Park S, Tomita-Yamaguchi M, Kanno T, Brown K, Siebenlist U: The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites [published erratum appears in EMBO J 16:440]. Embo J. 1997, 12: 3893-3901.CrossRef
37.
Benbow U, Brinckerhoff CE: The AP-1 site and MMP gene regulation: what is all the fuss about?. Matrix Biol. 1997, 15: 519-526. 10.1016/S0945-053X(97)90026-3.PubMedCrossRef
38.
Chamberlain SH, Hemmer RM, Brinckerhoff CE: Novel phorbol ester response region in the collagenase promoter binds Fos and Jun. J Cell Biochem. 1993, 52: 337-351.PubMedCrossRef
39.
White LA, Brinckerhoff CE: Two activator protein-1 elements in the matrix metalloproteinase-1 promoter have different effects on transcription and bind Jun D, c-Fos, and Fra-2. Matrix Biol. 1995, 14: 715-725.PubMedCrossRef
40.
Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS: Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther. 1999, 291: 124-130.PubMed
41.
Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998, 58: 5321-5325.PubMed
42.
Kanamori Y, Matsushima M, Minaguchi T, Kobayashi K, Sagae S, Kudo R, Terakawa N, Nakamura Y: Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res. 1999, 59: 4225-4227.PubMed
43.
Nishioka Y, Kobayashi K, Sagae S, Ishioka S, Nishikawa A, Matsushima M, Kanamori Y, Minaguchi T, Nakamura Y, Tokino T, Kudo R: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn J Cancer Res. 2000, 91: 612-615.PubMedPubMedCentralCrossRef
44.
Enomoto H, Enomoto-Iwamoto M, Iwamoto M, Nomura S, Himeno M, Kitamura Y, Kishimoto T, Komori T: Cbfa1 is a positive regulatory factor in chondrocyte maturation. J Biol Chem. 2000, 275: 8695-8702. 10.1074/jbc.275.12.8695.PubMedCrossRef
45.
Inada M, Yasui T, Nomura S, Miyake S, Deguchi K, Himeno M, Sato M, Yamagiwa H, Kimura T, Yasui N, Ochi T, Endo N, Kita-mura Y, Kishimoto T, Komori T: Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev Dyn. 1999, 214: 279-290. 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.3.CO;2-N.PubMedCrossRef
46.
Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T: Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997, 89: 755-764.PubMedCrossRef
47.
Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G: Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997, 89: 747-754.PubMedCrossRef
48.
Hess J, Porte D, Munz C, Angel P: AP-1 and Cbfa/runt physically interact and regulate parathyroid hormone-dependent MMP13 expression in osteoblasts through a new osteoblast-specific element 2/AP-1 composite element. J Biol Chem. 2001, 276: 20029-20038. 10.1074/jbc.M010601200.PubMedCrossRef
49.
Selvamurugan N, Chou WY, Pearman AT, Pulumati MR, Partridge NC: Parathyroid hormone regulates the rat collagenase-3 promoter in osteoblastic cells through the cooperative interaction of the activator protein-1 site and the runt domain binding sequence. J Biol Chem. 1998, 273: 10647-10657. 10.1074/jbc.273.17.10647.PubMedCrossRef
50.
Porte D, Tuckermann J, Becker M, Baumann B, Teurich S, Higgins T, Owen MJ, Schorpp-Kistner M, Angel P: Both AP-1 and Cbfa1-like factors are required for the induction of interstitial collagenase by parathyroid hormone. Oncogene. 1999, 18: 667-678. 10.1038/sj/onc/1202333.PubMedCrossRef
51.
Brown PD: Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Invest Drugs. 2000, 9: 2167-2177.CrossRef
52.
Funder JW: Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu Rev Med. 1997, 48: 231-240. 10.1146/annurev.med.48.1.231.PubMedCrossRef
53.
Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR: Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science. 1990, 249: 1266-1272.PubMedCrossRef
54.
Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS: Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol. 1995, 15: 943-953.PubMedPubMedCentralCrossRef
55.
Ray A, Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA. 1994, 91: 752-756.PubMedPubMedCentralCrossRef
56.
Tao Y, Williams-Skipp C, Scheinman RI: Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis. J Biol Chem. 2001, 276: 2329-2332. 10.1074/jbc.C000526200.PubMedCrossRef
57.
Pan L, Eckhoff C, Brinckerhoff CE: Suppression of collagenase gene expression by all-trans and 9-cis retinoic acid is ligand dependent and requires both RARs and RXRs. J Cell Biochem. 1995, 57: 575-589.PubMedCrossRef
58.
Schroen DJ, Brinckerhoff CE: Inhibition of rabbit collagenase (matrix metalloproteinase-1; MMP-1) transcription by retinoid receptors: evidence for binding of RARs/RXRs to the -77 AP-1 site through interactions with c-Jun. J Cell Physiol. 1996, 169: 320-332. 10.1002/(SICI)1097-4652(199611)169:2<320::AID-JCP11>3.3.CO;2-Z.PubMedCrossRef
59.
Yang-Yen HF, Zhang XK, Graupner G, Tzukerman M, Sakamoto B, Karin M, Pfahl M: Antagonism between retinoic acid receptors and AP-1: implications for tumor promotion and inflammation. New Biol. 1991, 3: 1206-1219.PubMed
60.
Schule R, Rangarajan P, Yang N, Kliewer S, Ransone LJ, Bolado J, Verma IM, Evans RM: Retinoic acid is a negative regulator of AP-1-responsive genes. Proc Natl Acad Sci USA. 1991, 88: 6092-6096.PubMedPubMedCentralCrossRef
61.
Schroen DJ, Brinckerhoff CE: Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms. Gene Expr. 1996, 6: 197-207.PubMed
62.
Kuwabara K, Shudo K, Hori Y: Novel synthetic retinoic acid inhibits rat collagen arthritis and differentially affects serum immunoglobulin subclass levels. FEBS Lett. 1996, 378: 153-156. 10.1016/0014-5793(95)01440-3.PubMedCrossRef
63.
Mix KS, Mengshol JA, Benbow U, Vincenti MP, Sporn MB, Brinckerhoff CE: A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum. 2001, 44: 1096-1104. 10.1002/1529-0131(200105)44:5<1096::AID-ANR190>3.3.CO;2-Y.PubMedCrossRef
64.
Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, Maue RA, Place AE, Porter DM, Spinella MJ, Williams CR, Wu G, Dannenberg AJ, Flanders KC, Letterio JJ, Mangelsdorf DJ, Nathan CF, Nguyen L, Porter WW, Ren RF, Roberts AB, Roche NS, Sub-baramaiah K, Sporn MB: A novel synthetic oleanane triter-penoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res. 1999, 59: 336-341.PubMed
65.
Wang Y, Porter WW, Suh N, Honda T, Gribble GW, Leesnitzer LM, Plunket KD, Mangelsdorf DJ, Blanchard SG, Willson TM, Sporn MB: A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol. 2000, 14: 1550-1556.PubMed
66.
Fahmi H, Di Battista JA, Pelletier JP, Mineau F, Ranger P, Martel-Pelletier J: Peroxisome proliferator–activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum. 2001, 44: 595-607. 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#.PubMedCrossRef
67.
Ridley SH, Sarsfield SJ, Lee JC, Bigg HF, Cawston TE, Taylor DJ, DeWitt DL, Saklatvala J: Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J Immunol. 1997, 158: 3165-3173.PubMed
68.
Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE: Pharmacological profile of SB 20 a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther. 3580, 279: 1453-1461.
69.
Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, Griswold DE, Winkler JD: Pharmacological effects of SB 22 a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther. 0025, 284: 687-692.
70.
Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, Stroup GB, Webb E, Rieman DJ, Gowen M, Boehm JC, Adams JL, Lee JC: Disease-modifying activity of SB 24 a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. 2235, 43: 175-183. 10.1002/1529-0131(200001)43:1<175::AID-ANR22>3.0.CO;2-S.CrossRef
71.
Firestein GS, Manning AM: Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum. 1999, 42: 609-621. 10.1002/1529-0131(199904)42:4<609::AID-ANR3>3.0.CO;2-I.PubMedCrossRef
72.
73.
Bondeson J, Foxwell B, Brennan F, Feldmann M: Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci USA. 1999, 96: 5668-5673. 10.1073/pnas.96.10.5668.PubMedPubMedCentralCrossRef
74.
Campbell IK, Gerondakis S, O'Donnell K, Wicks IP: Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest. 2000, 105: 1799-1806.PubMedPubMedCentralCrossRef
Metadata
Title
Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors
Authors
Matthew P Vincenti
Constance E Brinckerhoff
Publication date
01-04-2002
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2002
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar401

Other articles of this Issue 3/2002

Arthritis Research & Therapy 3/2002 Go to the issue

Research article

Combined antibiotic and free radical trap treatment is effective at combating Staphylococcus-aureus-induced septic arthritis

Research article

Production of interleukin-1 receptor antagonist by human articular chondrocytes

Research article

Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue

Research article

T-cell activation without proliferation in juvenile idiopathic arthritis

Announcement

Arthritis Research: the move to publish research articles in full online only

Research article

Tissue factor as a proinflammatory agent
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits